Liver Cancer Diagnostics Market Size, Share & Trends Analysis Report By Test Type (Laboratory Tests, Imaging, Endoscopy, Biopsy), By End-use, By Region, And Segment Forecasts, 2023 - 2030

Liver Cancer Diagnostics Market Size, Share & Trends Analysis Report By Test Type (Laboratory Tests, Imaging, Endoscopy, Biopsy), By End-use, By Region, And Segment Forecasts, 2023 - 2030

Liver Cancer Diagnostics Market Growth & Trends

The global liver cancer diagnostics market size is expected to reach USD 14.67 billion by 2030, advancing at a CAGR of 6.67% over the forecast period from 2023 to 2030, according to a new report by Grand View Research, Inc. The growing prevalence of liver cancer, the technological advancements for diagnosis, and the awareness of screening importance for treatment & survival rate are driving the market growth for liver cancer diagnostics.

According to the American Society of Cancer statistics in 2022, around 41,260 new cases are expected to be diagnosed with liver cancer. It was also presented by Globocan in 2020, that about 830,180 deaths were accounted by liver cancer worldwide. WHO also estimates that chronic hepatitis viral infections are widespread in the population, with hepatitis C virus (HCV) affecting about 58 million people. HCV and hepatitis B virus (HBV) are the most commonly associated risk factors of liver cancer. In addition, the infection prevalence and exposure to other risk factors such as cirrhosis and smoking will upsurge the demand for screening solutions for early treatment & diagnosis of liver cancer to increase the survival rate. Thus, the demand for diagnostics products will boost during the forecast period, thereby driving market growth.

The COVID-19 pandemic disrupted liver cancer patient care and resulted in higher mortality rates. The delayed or interrupted screening & procedures impacted the patients with the disease. For example, in a June 2021 article, researchers from European countries assessed the pandemic’s impact on routine care of liver cancer patients and concluded that the modifications significantly altered the outcomes. However, with advancements in technology and a better understanding of the immune system during COVID-19, many new healthcare diagnostic products have been launched. Moreover, the pandemic boosted the importance of health and pushed the population toward regular health screening for early diagnosis & treatment.

The technological advancement in diagnosis has resulted from increased awareness and supportive initiatives by many public-private organizations worldwide. This will result in a conducive environment to increase the screening as well as diagnosis of various cancers and is expected to propel the growth of diagnostics solutions. For example, in September 2022, Delfi Diagnostics, Inc., a U.S.-based diagnostics company, announced that it has been selected as the liquid biopsy partner in a large-scale screening trial in Europe.

To cater to the increased demand for innovative solutions for the early detection of liver cancer, multiple companies are launching new products. For instance, in March 2020, F. Hoffmann-La Roche Ltd. Roche received the ‘Breakthrough Device Designation’ from the US FDA for its new Elecsys GALAD score. The score supports clinicians in the diagnosis of hepatocellular carcinoma (HCC) by providing them with timely and accurate information. Key companies are also undergoing collaborations, agreements, and partnerships for new product developments. Such product developments & launches will intensify the market competition and fuel the market growth for liver cancer diagnostics.

Liver Cancer Diagnostics Market Report Highlights

  • On basis of test type, laboratory tests held the largest share in 2022, owing to the increased demand for accurate & cost-effective diagnosis of disease stages. In addition, the application of laboratory tests for monitoring response to treatment plans also propels the growth
  • Based on end-use, the hospitals and diagnostic laboratories segment dominated the market in 2022. The preference for these settings as primary care centers for the diagnosis and treatment with the help of medical professionals boosts the segment’s growth
  • North America accounted for the highest share in 2022 due to the prevalence of risk factors in the population. This has resulted from the increased awareness about disease screening and the growing adoption of advanced technologies in this region, driving the growth
  • Asia Pacific will exhibit the fastest growth during the forecast period of 2023-2030, owing to the prevalence of diseases and the presence of a large geriatric population in the region. In addition, the developing economies will boost the adoption of diagnostic tests in the region’s emerging countries
Please note The report will be delivered in 2-3 business days upon order notification.


Chapter 1 Methodology And Scope
1.1 Research Methodology
1.2 Research Assumptions
1.2.1 Estimates And Forecast Timeline
1.3 Information Procurement
1.3.1 Purchased Database
1.3.2 Gvr’s Internal Database
1.3.3 Secondary Sources
1.3.4 Primary Research
1.4 Information Or Data Analysis
1.4.1 Data Analysis Models
1.5 Market Formulation & Validation
Chapter 2 Executive Summary
2.1 Market Snapshot
2.2 Segment Snapshot
2.3 Competitive Landscape Snapshot
Chapter 3 Market Variables, Trends, & Scope
3.1 Parent Market Analysis
3.2 Market Dynamics
3.2.1 Market Driver Analysis
3.2.1.1 Increasing Prevalence Of Liver Cancer
3.2.1.2 Rising Initiatives Undertaken By Public And Private Organizations
3.2.1.3 Increasing Prevalence Of Risk Factors For Liver Cancer
3.2.1.4 Technological Advancements
3.2.2 Market Restraint Analysis
3.2.2.1 High Cost Of Diagnostic Imaging
3.2.2.2 Radiation Exposure Likely To Limit Usage Of Ct
3.3 Penetration & Growth Prospect Mapping
3.4 Liver Cancer Diagonstics Market - Porter’s Analysis
3.5 Liver Cancer Diagonstics Market - Swot Analysis
3.6 Covid-19 Impact Analysis
Chapter 4 Test Type Business Analysis
4.1 Liver Cancer Diagonstics Market - Test Type Movement Analysis
4.2 Laboratory Tests
4.2.1 Global Laboratory Tests Market, 2018 - 2030 (USD Million)
4.2.2 Biomarkers
4.2.2.1 Global Biomarkers Market, 2018 - 2030 (USD Million)
4.2.2.2 Oncofetal And Glycoprotein Antigens
4.2.2.2.1 Global Oncofetal And Glycoprotein Antigens Market, 2018 - 2030 (USD Million)
4.2.2.3 Enzymes And Isoenzymes
4.2.2.3.1 Global Enzymes And Isoenzymes Market, 2018 - 2030 (USD Million)
4.2.2.4 Growth Factors And Receptors
4.2.2.4.1 Global Growth Factors And Receptors Market, 2018 - 2030 (USD Million)
4.2.2.5 Molecular Markers
4.2.2.5.1 Global Molecular Markers Market, 2018 - 2030 (USD Million)
4.2.2.6 Pathological Biomarkers
4.2.2.6.1 Global Pathological Biomarkers Market, 2018 - 2030 (USD Million)
4.2.3 Blood Tests
4.2.3.1 Global Bloos Tests Market, 2018 - 2030 (USD Million)
4.3 Imaging
4.3.1 Global Imaging Market, 2018 - 2030 (USD Million)
4.4 Endoscopy
4.4.1 Global Endoscopy Market, 2018 - 2030 (USD Million)
4.5 Biopsy
4.5.1 Global Biopsy Market, 2018 - 2030 (USD Million)
4.6 Others
4.6.1 Global Other Tests Type Market, 2018 - 2030 (USD Million)
Chapter 5 End-Use Business Analysis
5.1 Liver Cancer Diagonstics Market-End Use Movement Analysis
5.2 Hospitals & Diagnostic Laboratories
5.2.1 Global Hospitals & Diagnostic Laboratories Market, 2018 - 2030 (USD Million)
5.3 Academic & Research Institutes
5.3.1 Global Academic & Research Institutes Market, 2018 - 2030 (USD Million)
5.4 Pharmaceutical & Cro Laboratories
5.4.1 Global Pharmaceutical & Cro Laboratories Market, 2018 - 2030 (USD Million)
Chaper 6 Regional Business Analysis
6.1 Liver Cancer Diagonstics Market: Regional Movement Analysis
6.2 North America
6.2.1 Swot Analysis
6.2.1.1 North America Liver Cancer Diagnostics Market Estimates And Forecast, 2018 - 2030 (USD Million)
6.2.2 U.S.
6.2.2.1 Key Country Dynamics
6.2.2.2 Competitive Scenario
6.2.2.3 U.S. Liver Cancer Diagnostics Market, 2018 - 2030 (USD Million)
6.2.3 Rest Of Europe
6.2.3.1 Key Country Dynamics
6.2.3.2 Competitive Scenario
6.2.3.3 Rest Of Europe Liver Cancer Diagnostics Market, 2018 - 2030 (USD Million)
6.3 Europe
6.3.1 Swot Analysis
6.3.1.1 Europe Liver Cancer Diagnostics Market Estimates And Forecast, 2018 - 2030 (USD Million)
6.3.2 U.K.
6.3.2.1 Key Country Dynamics
6.3.2.2 Competitive Scenario
6.3.2.3 U.K. Liver Cancer Diagnostics Market, 2018 - 2030 (USD Million)
6.3.3 Germany
6.3.3.1 Key Country Dynamics
6.3.3.2 Competitive Scenario
6.3.3.3 Germany Liver Cancer Diagnostics Market, 2018 - 2030 (USD Million)
6.3.4 France
6.3.4.1 Key Country Dynamics
6.3.4.2 Competitive Scenario
6.3.4.3 France Liver Cancer Diagnostics Market, 2018 - 2030 (USD Million)
6.3.5 Italy
6.3.5.1 Key Country Dynamics
6.3.5.2 Competitive Scenario
6.3.5.3 Italy Liver Cancer Diagnostics Market, 2018 - 2030 (USD Million)
6.3.6 Spain
6.3.6.1 Key Country Dynamics
6.3.6.2 Competitive Scenario
6.3.6.3 Spain Liver Cancer Diagnostics Market, 2018 - 2030 (USD Million)
6.3.7 Denmark
6.3.7.1 Key Country Dynamics
6.3.7.2 Competitive Scenario
6.3.7.3 Denmark Liver Cancer Diagnostics Market, 2018 - 2030 (USD Million)
6.3.8 Sweden
6.3.8.1 Key Country Dynamics
6.3.8.2 Competitive Scenario
6.3.8.3 Sweden Liver Cancer Diagnostics Market, 2018 - 2030 (USD Million)
6.3.9 Norway
6.3.9.1 Key Country Dynamics
6.3.9.2 Competitive Scenario
6.3.9.3 Norway Liver Cancer Diagnostics Market, 2018 - 2030 (USD Million)
6.3.10 Rest Of Europe
6.3.10.1 Key Country Dynamics
6.3.10.2 Competitive Scenario
6.3.10.3 Rest Of Europe Liver Cancer Diagnostics Market, 2018 - 2030 (USD Million)
6.4 Asia Pacific
6.4.1 Swot Analysis
6.4.1.1 Asia Pacific Liver Cancer Diagnostics Market Estimates And Forecast, 2018 - 2030 (USD Million)
6.4.2 Japan
6.4.2.1 Key Country Dynamics
6.4.2.2 Competitive Scenario
6.4.2.3 Japan Liver Cancer Diagnostics Market, 2018 - 2030 (USD Million)
6.4.3 China
6.4.3.1 Key Country Dynamics
6.4.3.2 Competitive Scenario
6.4.3.3 China Liver Cancer Diagnostics Market, 2018 - 2030 (USD Million)
6.4.4 India
6.4.4.1 Key Country Dynamics
6.4.4.2 Competitive Scenario
6.4.4.3 India Liver Cancer Diagnostics Market, 2018 - 2030 (USD Million)
6.4.5 South Korea
6.4.5.1 Key Country Dynamics
6.4.5.2 Competitive Scenario
6.4.5.3 South Korea Liver Cancer Diagnostics Market, 2018 - 2030 (USD Million)
6.4.6 Australia
6.4.6.1 Key Country Dynamics
6.4.6.2 Competitive Scenario
6.4.6.3 Australia Liver Cancer Diagnostics Market, 2018 - 2030 (USD Million)
6.4.7 Thailand
6.4.7.1 Key Country Dynamics
6.4.7.2 Competitive Scenario
6.4.7.3 Thailand Liver Cancer Diagnostics Market, 2018 - 2030 (USD Million)
6.4.8 Rest Of Asia Pacific
6.4.8.1 Key Country Dynamics
6.4.8.2 Competitive Scenario
6.4.8.3 Rest Of Apac Liver Cancer Diagnostics Market, 2018 - 2030 (USD Million)
6.5 Latin America
6.5.1 Swot Analysis
6.5.1.1 Latin America Liver Cancer Diagnostics Market Estimates And Forecast, 2018 - 2030 (USD Million)
6.5.2 Brazil
6.5.2.1 Key Country Dynamics
6.5.2.2 Competitive Scenario
6.5.2.3 Brazil Liver Cancer Diagnostics Market, 2018 - 2030 (USD Million)
6.5.3 Mexico
6.5.3.1 Key Country Dynamics
6.5.3.2 Competitive Scenario
6.5.3.3 Mexico Liver Cancer Diagnostics Market, 2018 - 2030 (USD Million)
6.5.4 Argentina
6.5.4.1 Key Country Dynamics
6.5.4.2 Competitive Scenario
6.5.4.3 Argentina Liver Cancer Diagnostics Market, 2018 - 2030 (USD Million)
6.5.5 Rest Of Latin America
6.5.5.1 Key Country Dynamics
6.5.5.2 Competitive Scenario
6.5.5.3 Rest Of Latam Liver Cancer Diagnostics Market, 2018 - 2030 (USD Million)
6.6 Middle East & Africa (Mea)
6.6.1 Swot Analysis
6.6.1.1 Mea Liver Cancer Diagnostics Market Estimates And Forecast, 2018 - 2030 (USD Million)
6.6.2 South Africa
6.6.2.1 Key Country Dynamics
6.6.2.2 Competitive Scenario
6.6.2.3 South Africa Liver Cancer Diagnostics Market, 2018 - 2030 (USD Million)
6.6.3 Rest Of Middle East & Africa
6.6.3.1 Key Country Dynamics
6.6.3.2 Competitive Scenario
6.6.3.3 Rest Of Middle East & Africa Liver Cancer Diagnostics Market, 2018 - 2030 (USD Million)
6.6.4 Uae
6.6.4.1 Key Country Dynamics
6.6.4.2 Competitive Scenario
6.6.4.3 Uae Liver Cancer Diagnostics Market, 2018 - 2030 (USD Million)
6.6.5 Kuwait
6.6.5.1 Key Country Dynamics
6.6.5.2 Competitive Scenario
6.6.5.3 Kuwait Liver Cancer Diagnostics Market, 2018 - 2030 (USD Million)
6.6.6 Rest Of Mea
6.6.6.1 Key Country Dynamics
6.6.6.2 Competitive Scenario
6.6.6.3 Rest Of Mea Liver Cancer Diagnostics Market, 2018 - 2030 (USD Million)
Chapter 7 Competitive Landscape
7.1 Participant’s Overview
7.1.1 Abbott Laboratories
7.1.2 Thermo Fisher Scientific, Inc.
7.1.3 F. Hoffmann-La Roche Ltd.
7.1.4 Qiagen N.V.
7.1.5 Seimens Healthineers
7.1.6 Becton, Dickinson & Company
7.1.7 Fujifilm Medical Systems U.S.A., Inc.
7.1.8 Illumina, Inc.
7.1.9 Epigenomics Ag
7.1.10 Koninklijke Philips N.V.
7.2 Financial Performance
7.3 Participant Categorization
7.3.1 Market Leaders
7.3.1.1 Liver Cancer Diagnostics Market Share Analysis, 2022
7.3.2 Strategy Mapping
7.3.2.1 Expansion
7.3.2.2 Acquisition
7.3.2.3 Collaborations
7.3.2.4 Product/Service Launch
7.3.2.5 Partnerships
7.3.2.6 Others

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook
Cookie Settings